Rapidly Progressive White Matter Involvement in Early Childhood: The Expanding Phenotype of Infantile Onset Pompe?

Research Report
Part of the JIMD Reports book series (JIMD, volume 39)


Glycogen accumulation in the central nervous system of patients with classical infantile onset Pompe disease (IOPD) has been a consistent finding on the few post-mortems performed. While delays in myelination and a possible reduction in processing speed have previously been noted, it has only been recently that the potential for clinically significant progressive white matter disease has been noted. The limited reports thus far published infer that in some IOPD patients, this manifests as intellectual decline in the second decade of life. We present a CRIM negative patient, immunomodulated with rituximab and methotrexate at birth, who despite an initial good clinical response to ERT, at the age of just under 4 years, presented with evolving spasticity in the lower limbs. The investigation of which revealed progressive central nervous system involvement. Given both the earlier onset of the symptoms and consanguineous familial pedigree, extensive biochemical and genetic investigation was undertaken to ensure no alternative pathology was elucidated. In light of these findings, we review the radiology and post-mortems of previous cases and discuss the potential mechanisms that may underlie this presentation.


CRIM negative Enzyme replacement therapy Glycogen Infantile onset Pompe disease Lysosomal storage White matter disease 


  1. Aylett SB, Neergheen V, Hargreaves IP, Eaton S, Land JM, Rahman S, Heales SJ (2013) Levels of 5-methyltetrahydrofolate and ascorbic acid in cerebrospinal fluid are correlated: implications for the accelerated degradation of folate by reactive oxygen species. Neurochem Int 63:750–755CrossRefPubMedGoogle Scholar
  2. Beesley CE, Child AH, Yacoub MH (1998) The identification of five novel mutations in the lysosomal acid a-(1-4) glucosidase gene from patients with glycogen storage disease type II. Mutations in brief no. 134. Online. Hum Mutat 11:413CrossRefPubMedGoogle Scholar
  3. Bercury KK, Dai J, Sachs HH, Ahrendsen JT, Wood TL, Macklin WB (2014) Conditional ablation of raptor or rictor has differential impact on oligodendrocyte differentiation and CNS myelination. J Neurosci 34:4466–4480CrossRefPubMedPubMedCentralGoogle Scholar
  4. Bercury KK, Macklin WB (2015) Dynamics and mechanisms of CNS myelination. Dev Cell 32:447–458CrossRefPubMedGoogle Scholar
  5. Broomfield A, Fletcher J, Davison J et al (2016) Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy. J Inherit Metab Dis 39:261–271CrossRefPubMedGoogle Scholar
  6. Burrow TA, Bailey LA, Kinnett DG, Hopkin RJ (2010) Acute progression of neuromuscular findings in infantile Pompe disease. Pediatr Neurol 42:455–458CrossRefPubMedGoogle Scholar
  7. Byrne BJ, Kishnani PS, Case LE, Merlini L, Muller-Felber W, Prasad S, van der Ploeg A (2011) Pompe disease: design, methodology, and early findings from the Pompe Registry. Mol Genet Metab 103:1–11CrossRefPubMedGoogle Scholar
  8. Chen CP, Lin SP, Tzen CY, Tsai FJ, Hwu WL, Wang W (2004) Detection of a homozygous D645E mutation of the acid alpha-glucosidase gene and glycogen deposition in tissues in a second-trimester fetus with infantile glycogen storage disease type II. Prenat Diagn 24:231–232CrossRefPubMedGoogle Scholar
  9. Chien YH, Lee NC, Peng SF, Hwu WL (2006) Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy. Pediatr Res 60:349–352CrossRefPubMedGoogle Scholar
  10. Ebbink BJ, Aarsen FK, van Gelder CM et al (2012) Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy. Neurology 78:1512–1518CrossRefPubMedGoogle Scholar
  11. Ebbink BJ, Poelman E, Plug I, Lequin MH, van Doorn PA, Aarsen FK, van der Ploeg AT, van den Hout JMP (2016) Cognitive decline in classic infantile Pompe disease: an underacknowledged challenge. Neurology 86:1260–1261CrossRefPubMedGoogle Scholar
  12. Ellingford JM, Barton S, Bhaskar S et al (2016) Molecular findings from 537 individuals with inherited retinal disease. J Med Genet 53:761–767CrossRefPubMedPubMedCentralGoogle Scholar
  13. Gambetti P, DiMauro S, Baker L (1971) Nervous system in Pompe’s disease. Ultrastructure and biochemistry. J Neuropathol Exp Neurol 30:412–430CrossRefPubMedGoogle Scholar
  14. Ghosh A, Schlecht H, Heptinsall LE et al (2017) Diagnosing childhood-onset inborn errors of metabolism by next-generation. doi:10.1136/archdischild-2017-312737Google Scholar
  15. Hensiek A, Kirker S, Reid E (2015) Diagnosis, investigation and management of hereditary spastic paraplegias in the era of next-generation sequencing. J Neurol 262:1601–1612CrossRefPubMedGoogle Scholar
  16. Hers HG (1963) Alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe’s disease). Biochem J 86:11–16CrossRefPubMedPubMedCentralGoogle Scholar
  17. Jelcic I, Jelcic I, Faigle W, Sospedra M, Martin R (2015) Immunology of progressive multifocal leukoencephalopathy. J Neurovirol 21:614–622CrossRefPubMedGoogle Scholar
  18. Kishnani PS, Goldenberg PC, DeArmey SL et al (2010) Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99:26–33CrossRefPubMedPubMedCentralGoogle Scholar
  19. Lim JA, Li L, Raben N (2014) Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci 6:177CrossRefPubMedPubMedCentralGoogle Scholar
  20. Lim JA, Li L, Shirihai OS, Trudeau KM, Puertollano R, Raben N (2017) Modulation of mTOR signaling as a strategy for the treatment of Pompe disease. EMBO Mol Med 9:353–370CrossRefPubMedPubMedCentralGoogle Scholar
  21. Mancall EL, Aponte GE, Berry RG (1965) Pompe’s disease (diffuse Glycogenosis) with neuronal storage. J Neuropathol Exp Neurol 24:85–96CrossRefPubMedGoogle Scholar
  22. Martin JJ, De Barsy T, De S, Leroy JG, Palladini G (1976) Acid maltase deficiency in non-identical adult twins. A morphological and biochemical study. J Neurol 213:105–118CrossRefPubMedGoogle Scholar
  23. Martin JJ, de Barsy T, van Hoof F, Palladini G (1973) Pompe’s disease: an inborn lysosomal disorder with storage of glycogen. A study of brain and striated muscle. Acta Neuropathol 23:229–244CrossRefPubMedGoogle Scholar
  24. Martini C, Ciana G, Benettoni A, Katouzian F, Severini GM, Bussani R, Bembi B (2001) Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2. Neurology 57:906–908CrossRefPubMedGoogle Scholar
  25. Prunty H, Man WC, Carey T, Lukovic B, Heales S (2015) Improved method for the analysis of urinary glucose tetrasaccharide (Glc4) by high pressure liquid chromatography (HPLC). Mol Genet Metab 114:S97–S97CrossRefGoogle Scholar
  26. Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405–424CrossRefPubMedPubMedCentralGoogle Scholar
  27. Rohrbach M, Klein A, Kohli-Wiesner A et al (2010) CRIM-negative infantile Pompe disease: 42-month treatment outcome. J Inherit Metab Dis 33:751–757CrossRefPubMedGoogle Scholar
  28. Shotelersuk V, Shuangshoti S, Chotivitayatarakorn P et al (2002) Clinical, pathological, and electron microscopic findings in two Thai children with Pompe disease. J Med Assoc Thail 85(Suppl 1):S271–S279Google Scholar
  29. Spiridigliozzi GA, Heller JH, Kishnani PS et al (2013) Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy. Neurology 80:1173CrossRefPubMedGoogle Scholar
  30. Teng YT, Su WJ, Hou JW, Huang SF (2004) Infantile-onset glycogen storage disease type II (Pompe disease): report of a case with genetic diagnosis and pathological findings. Chang Gung Med J 27:379–384PubMedGoogle Scholar
  31. van den Hout HM, Hop W, van Diggelen OP et al (2003) The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112:332–340CrossRefPubMedGoogle Scholar
  32. Vanderver A, Prust M, Tonduti D et al (2015) Case definition and classification of leukodystrophies and leukoencephalopathies. Mol Genet Metab 114:494–500CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© SSIEM and Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Willink Biochemical Genetics UnitManchester Centre for Genomic Medicine, St Mary’s Hospital, Central Manchester Foundation TrustManchesterUK
  2. 2.Department of PhysiotherapyRoyal Manchester Children’s Hospital, Central Manchester Foundation TrustManchesterUK
  3. 3.Manchester Centre for Genomic Medicine, St Mary’s Hospital, Central Manchester Foundation TrustManchesterUK
  4. 4.Department of BiochemistryGreat Ormond Street HospitalLondonUK
  5. 5.Department of Paediatric NeuroradiologyRoyal Manchester Children’s Hospital, Central Manchester Foundation TrustManchesterUK

Personalised recommendations